Brussels 'disappointed' by low take up of child medicine authorisation system

Published: 5-Oct-2012
Regulatory

Launches a public consultation about impact of the regulation


The European Commission (EC) has admitted being ‘disappointed’ by the low take-up of a special European Union (EU) Paediatric Use Marketing Authorisation (PUMA) designed to encourage the development of medicines for children.

Introduced by the EU’s paediatric regulation (EC) No 1901/2006, only one PUMA authorisation has been issued since the legislation came into force. This is despite it offering 10 years of data and market exclusivity to any new off-patent product developed exclusively for children.

In a consultation report on the performance of the regulation, the Commission added: ‘Neither industry nor academic networks have responded to this opportunity as widely as the regulation intended and aimed for. It would seem that the incentive of data and market exclusivity does not work for those products, or market opportunities are currently considered insufficient to outweigh the inherent economic risks of pharmaceutical development.’

The EC has launched a public consultation about the regulation’s impact, in which it asks for reasons why this low take-up has happened.

Among other questions asked, the Commission requests comments on articles 45 and 46 of the law, where companies are required to give to regulators data on the safety or efficacy of medicines authorised for treating children. This has enabled regulators to assess and issue guidance on whether 140 active substances should be used in paediatric medicines. It said since 2008 more than 18,000 study reports on roughly 2,200 medicinal products had been submitted ‘revealing the large amount of existing paediatric information available at company level’. This has been assessed through ‘an impressive work-sharing project.

The consultation will feed into a 2013 report. Comments should me made by 28 November to sanco-pharmaceuticals-D5@ec.europa.eu.

Meanwhile, the European Medicines Agency (EMA) has released a discussion paper on how children and young people’s views and comments could be used in its market approval assessments of paediatric medicines.

See more

You may also like

Regulatory

How the EU's AI Act of 2024 will impact businesses using the technology

Read more
The legally binding rules on AI use aim to enhance the reliability and safety of the technology's implementation globally

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

How the EU's AI Act of 2024 will impact businesses using the technology

The legally binding rules on AI use aim to enhance the reliability and safety of the technology's implementation globally
Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Distribution

Moderna receives positive opinion from the EMA for Spikevax

Moderna has revealed the European Medicine's Agency (EMA) has provided positive opinion on its COVID-19 vaccine Spikevax's marketing authorisation
Regulatory

Timber Pharmaceuticals receives EC orphan drug designation

TMB-001 is a topical isotretinoin, formulated using the company’s patented IPEG delivery system
Regulatory

European Commission purchases additional Moderna vaccine doses

Under the terms of the agreement, the European Commission has the option to purchase an additional 150 million doses to be delivered in 2022
Regulatory

EMA celebrates 25 years of regulatory management

The EMA was founded in January 1995
Regulatory

EMA publishes draft guideline on quality requirements for DDCs

The latest document focuses on combinations of medicinal products and medical devices
Subscribe now